116 related articles for article (PubMed ID: 19881523)
1. The role of p53 in limiting somatic cell reprogramming.
Liu Y; Hoya-Arias R; Nimer SD
Cell Res; 2009 Nov; 19(11):1227-8. PubMed ID: 19881523
[No Abstract] [Full Text] [Related]
2. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
3. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation.
Sashida G; Liu Y; Elf S; Miyata Y; Ohyashiki K; Izumi M; Menendez S; Nimer SD
Mol Cell Biol; 2009 Jul; 29(13):3687-99. PubMed ID: 19380490
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
Giono LE; Manfredi JJ
Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal stress induces L11- and p53-dependent apoptosis in mouse pluripotent stem cells.
Morgado-Palacin L; Llanos S; Serrano M
Cell Cycle; 2012 Feb; 11(3):503-10. PubMed ID: 22262176
[TBL] [Abstract][Full Text] [Related]
6. p21 delays tumor onset by preservation of chromosomal stability.
Barboza JA; Liu G; Ju Z; El-Naggar AK; Lozano G
Proc Natl Acad Sci U S A; 2006 Dec; 103(52):19842-7. PubMed ID: 17170138
[TBL] [Abstract][Full Text] [Related]
7. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
8. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
9. The role of cell cycle regulatory proteins in the pathogenesis of melanoma.
Li W; Sanki A; Karim RZ; Thompson JF; Soon Lee C; Zhuang L; McCarthy SW; Scolyer RA
Pathology; 2006 Aug; 38(4):287-301. PubMed ID: 16916716
[TBL] [Abstract][Full Text] [Related]
10. Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21(WAF1/CIP1).
Huschtscha LI; Moore JD; Noble JR; Campbell HG; Royds JA; Braithwaite AW; Reddel RR
J Cell Sci; 2009 Aug; 122(Pt 16):2989-95. PubMed ID: 19638413
[TBL] [Abstract][Full Text] [Related]
11. Mdm2, p53, p21 and pAKT protein pathways in benign neoplasms of the salivary gland.
Marques YM; de Lima Mde D; de Melo Alves Sde M; Soares FA; de Araújo VC; Pinto Ddos S; Mantesso A
Oral Oncol; 2008 Sep; 44(9):903-8. PubMed ID: 18485798
[TBL] [Abstract][Full Text] [Related]
12. Synaptotagmin-7, a binding protein of P53, inhibits the senescence and promotes the tumorigenicity of lung cancer cells.
Fei Z; Gao W; Xie R; Feng G; Chen X; Jiang Y
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647108
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer.
Barton MC; Akli S; Keyomarsi K
J Cell Physiol; 2006 Dec; 209(3):686-94. PubMed ID: 17001684
[TBL] [Abstract][Full Text] [Related]
14. P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation.
Chazal M; Marionnet C; Michel L; Mollier K; Dazard JE; Della Valle V; Larsen CJ; Gras MP; Basset-Séguin N
Oncogene; 2002 Apr; 21(17):2652-61. PubMed ID: 11965538
[TBL] [Abstract][Full Text] [Related]
15. Δ133p53 represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells.
Horikawa I; Park KY; Isogaya K; Hiyoshi Y; Li H; Anami K; Robles AI; Mondal AM; Fujita K; Serrano M; Harris CC
Cell Death Differ; 2017 Jun; 24(6):1017-1028. PubMed ID: 28362428
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide overcomes pluripotency deficits and reprogramming barriers.
Son MJ; Son MY; Seol B; Kim MJ; Yoo CH; Han MK; Cho YS
Stem Cells; 2013 Jun; 31(6):1121-35. PubMed ID: 23526681
[TBL] [Abstract][Full Text] [Related]
17. Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation.
Osabe M; Sugatani J; Takemura A; Yamazaki Y; Ikari A; Kitamura N; Negishi M; Miwa M
Biochem Biophys Res Commun; 2008 May; 369(4):1027-33. PubMed ID: 18331826
[TBL] [Abstract][Full Text] [Related]
18. The ups and downs of p53 regulation in hematopoietic stem cells.
Abbas HA; Pant V; Lozano G
Cell Cycle; 2011 Oct; 10(19):3257-62. PubMed ID: 21957490
[TBL] [Abstract][Full Text] [Related]
19. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
[TBL] [Abstract][Full Text] [Related]
20. Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency.
Menendez S; Camus S; Herreria A; Paramonov I; Morera LB; Collado M; Pekarik V; Maceda I; Edel M; Consiglio A; Sanchez A; Li H; Serrano M; Belmonte JC
Aging Cell; 2012 Feb; 11(1):41-50. PubMed ID: 21981310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
